{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:24:39Z","timestamp":1793381079345,"version":"4.5.0"},"reference-count":108,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"unspecified","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/igo\/"}],"funder":[{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"crossref","award":["2024\/1462426-0"],"award-info":[{"award-number":["2024\/1462426-0"]}],"id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Glob Health"],"accepted":{"date-parts":[[2025,10,8]]},"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Given the critical role of medicines in reducing the burden of non-communicable diseases (NCDs), we analysed factors that hinder the availability of quality medicines for managing NCDs at the point of service delivery, with a particular focus on low-income and middle-income countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this scoping review, literature published in PubMed, Embase, Web of Science, the World Bank eLibrary and the WHO\u2019s Institutional Repository for Information Sharing (WHO IRIS) was collected (January 2009\u2013May 2025). Literature was excluded if it did not specifically address NCD medicines, discussed global rather than national determinants of availability only, failed to detail supply chain inefficiencies or exclusively reported on other dimensions of access (ie, pricing\/affordability, trial access, regulatory access). From cross-sectional assessments of medicine availability, mean availability was extracted, and from quantitative, interventional studies, details on the intervention and its effectiveness on NCD medicine availability were extracted. From the remaining studies, descriptions of barriers and recommendations or empirically proven interventions to improve availability were extracted and mapped according to the pharmaceutical value chain (PVC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our review of 3348 records identified 83 eligible studies. The mean availability of NCD medicines reported in cross-sectional surveys was suboptimal (&lt;80%) in 39 of 46 surveyed countries. We found barriers to available NCD medicines across all components of the PVC. Deficiencies in governance, financing, the health workforce, health information systems and service delivery underscore the interlinkage of various health system building blocks and stakeholders in determining availability. Nonetheless, most barriers pertained to supply chain inefficiencies, followed by challenges in regulatory systems and quality monitoring.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The evidence highlights the need for political commitment to NCDs, broad stakeholder involvement, integrated stock management systems and increased human resources to make NCD medicines more available to patients worldwide.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjgh-2025-019634","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T13:30:15Z","timestamp":1764250215000},"page":"e019634","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Availability of essential medicines for non-communicable diseases: a scoping review of challenges and opportunities"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7677-8589","authenticated-orcid":false,"given":"Iris R","family":"Joosse","sequence":"first","affiliation":[{"name":"Utrecht WHO Collaborating Centre for Pharmaceutical Policy and Regulation, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8782-0698","authenticated-orcid":false,"given":"Aukje","family":"Mantel-Teeuwisse","sequence":"additional","affiliation":[{"name":"Utrecht WHO Collaborating Centre for Pharmaceutical Policy and Regulation, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1339-9818","authenticated-orcid":false,"given":"Hendrika A","family":"van den Ham","sequence":"additional","affiliation":[{"name":"Utrecht WHO Collaborating Centre for Pharmaceutical Policy and Regulation, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes","family":"Cantarero Arevalo","sequence":"additional","affiliation":[{"name":"WHO Collaborating Center for Research and Training in the Patient Perspective on Medicines Use, Department of Pharmacy, Faculty of health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"2025112705300699000_10.11.e019634.1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1223466"},{"key":"2025112705300699000_10.11.e019634.2","unstructured":"World Health Organization . The double burden: emerging epidemics and persistent problems. In: The world health report 1999: making a difference. Geneva, 1999."},{"key":"2025112705300699000_10.11.e019634.3","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/S0140-6736(18)31992-5","article-title":"NCD Countdown 2030: worldwide trends in non-communicable disease mortality and progress towards Sustainable Development Goal target 3.4","volume":"392","author":"Bennett","year":"2018","journal-title":"The Lancet"},{"key":"2025112705300699000_10.11.e019634.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01301-6"},{"key":"2025112705300699000_10.11.e019634.5","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101675","article-title":"Quantifying the global burden of mental disorders and their economic value","volume":"54","author":"Arias","year":"2022","journal-title":"EClinicalMedicine"},{"key":"2025112705300699000_10.11.e019634.6","unstructured":"World Health Organization . WHA 66.10. follow-up to the political declaration of the high-level meeting of the general assembly on the prevention and control of non-communicable diseases. In: Sixty-Sixth World Health Assembly, Geneva, 20\u201327 May 2013. Resolutions And Decisions, Annexes. Geneva, 2013."},{"key":"2025112705300699000_10.11.e019634.7","unstructured":"World Health Organization . Global action plan for the prevention and control of noncommunicable diseases, 2013-2020. Geneva, 2013."},{"key":"2025112705300699000_10.11.e019634.8","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.10.084327"},{"key":"2025112705300699000_10.11.e019634.9","unstructured":"United Nations General Assembly . A\/res\/70\/1. transforming our world: the 2030 agenda for sustainable development. New York: United Nations, 2015."},{"key":"2025112705300699000_10.11.e019634.10","unstructured":"World Health Organization . Assessing national capacity for the prevention and control of noncommunicable diseases: report of the 2019 global survey. Geneva, 2020."},{"key":"2025112705300699000_10.11.e019634.11","doi-asserted-by":"crossref","DOI":"10.1177\/1178632920986233","article-title":"Public Sector Capacity to Prevent and Control of Noncommunicable Diseases in Twelve Low- and Middle-Income Countries Based on WHO-PEN Standards: A Systematic Review","volume":"14","author":"Albelbeisi","year":"2021","journal-title":"Health Serv Insights"},{"key":"2025112705300699000_10.11.e019634.12","doi-asserted-by":"crossref","first-page":"e390","DOI":"10.1016\/S2468-2667(17)30168-8","article-title":"Beyond availability and affordability: how access to medicines affects non-communicable disease outcomes","volume":"2","author":"Wirtz","year":"2017","journal-title":"Lancet Public Health"},{"key":"2025112705300699000_10.11.e019634.13","unstructured":"World Health Organization . Mid-point evaluation of the implementation of the who global action plan for the prevention and control of noncommunicable diseases 2013-2020 (ncd-gap). volume 1: report. Geneva, 2020."},{"key":"2025112705300699000_10.11.e019634.14","unstructured":"World Health Organization . WHO discussion paper for the regional expert consultations: development of an implementation roadmap 2023\u20132030 for the global action plan for the prevention and control of ncds 2013\u20132030. Geneva, 2021."},{"key":"2025112705300699000_10.11.e019634.15","unstructured":"Penchansky R , Miralles M , Walkowiak H , et al . Defining and Measuring Access to Essential Drugs, Vaccines, and Health Commodities: Report of the WHO-MSH Consultative Meeting. Arlington: Centre for Pharmaceutical Management, 2003."},{"key":"2025112705300699000_10.11.e019634.16","doi-asserted-by":"crossref","DOI":"10.1186\/s13104-024-06764-1","article-title":"A proposed analytical framework for qualitative evaluation of access to medicines from a health systems perspective","volume":"17","author":"Joosse","year":"2024","journal-title":"BMC Res Notes"},{"key":"2025112705300699000_10.11.e019634.17","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s42256-020-00287-7","article-title":"An open source machine learning framework for efficient and transparent systematic reviews","volume":"3","author":"van de Schoot","year":"2021","journal-title":"Nat Mach Intell"},{"key":"2025112705300699000_10.11.e019634.18","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.01375","article-title":"The Availability, Pricing, and Affordability of Essential Diabetes Medicines in 17 Low-, Middle-, and High-Income Countries","volume":"10","author":"Babar","year":"2019","journal-title":"Front Pharmacol"},{"key":"2025112705300699000_10.11.e019634.19","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s40199-022-00454-8","article-title":"Availability and affordability of cardiovascular medicines in a major city of Afghanistan in 2020","volume":"30","author":"Kokabisaghi","year":"2022","journal-title":"DARU J Pharm Sci"},{"key":"2025112705300699000_10.11.e019634.20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229307","article-title":"Availability, cost and affordability of essential cardiovascular disease medicines in the south west region of Cameroon: Preliminary findings from the Cameroon science for disease study","volume":"15","author":"Dzudie","year":"2020","journal-title":"PLoS ONE"},{"key":"2025112705300699000_10.11.e019634.21","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1177\/1010539517700472","article-title":"Availability, Price, and Affordability of Selected Essential Medicines for Chronic Diseases in 11 Countries of the Asia Pacific Region: A Secondary Analysis","volume":"29","author":"Wang","year":"2017","journal-title":"Asia Pac J Public Health"},{"key":"2025112705300699000_10.11.e019634.22","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.2147\/RMHP.S395456","article-title":"Price, Availability and Affordability of Anti-Cancer Medicines in Addis Ababa, Ethiopia","volume":"15","author":"Alemu","year":"2022","journal-title":"Risk Manag Healthc Policy"},{"key":"2025112705300699000_10.11.e019634.23","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-021-08435-x","article-title":"Evaluating essential medicines for treating childhood cancers: availability, price and affordability study in Ghana","volume":"21","author":"Mensah","year":"2021","journal-title":"BMC Cancer"},{"key":"2025112705300699000_10.11.e019634.24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0279817","article-title":"A comprehensive survey of cancer medicines prices, availability and affordability in Ghana","volume":"18","author":"Ocran Mattila","year":"2023","journal-title":"PLoS ONE"},{"key":"2025112705300699000_10.11.e019634.25","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2018-001379","article-title":"Evaluating access to essential medicines for treating childhood cancers: a medicines availability, price and affordability study in New Delhi, India","volume":"4","author":"Faruqui","year":"2019","journal-title":"BMJ Glob Health"},{"key":"2025112705300699000_10.11.e019634.26","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1111\/tmi.13494","article-title":"Availability, price and affordability of essential medicines for managing cardiovascular diseases and diabetes: a statewide survey in Kerala, India","volume":"25","author":"Satheesh","year":"2020","journal-title":"Trop Med Int Health"},{"key":"2025112705300699000_10.11.e019634.27","doi-asserted-by":"crossref","first-page":"473","DOI":"10.26719\/emhj.18.068","article-title":"Availability, pricing and affordability of selected medicines for noncommunicable diseases","volume":"25","author":"Heidari","year":"2019","journal-title":"East Mediterr Health J"},{"key":"2025112705300699000_10.11.e019634.28","first-page":"64","article-title":"The Availability and Affordability of Cardiovascular Medicines for Secondary Prevention in Tehran Province (Iran)","volume":"17","author":"Farahani","year":"2018","journal-title":"Iran J Pharm Res"},{"key":"2025112705300699000_10.11.e019634.29","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1186\/s12913-019-4828-0","article-title":"Relationship between pharmaceutical pricing strategies with price, availability, and affordability of cardiovascular disease medicines: surveys in Qatar and Lebanon","volume":"19","author":"Abdel Rida","year":"2019","journal-title":"BMC Health Serv Res"},{"key":"2025112705300699000_10.11.e019634.30","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-020-05167-9","article-title":"Availability, prices, and affordability of selected essential cancer medicines in a middle-income country - the case of Mexico","volume":"20","author":"Moye-Holz","year":"2020","journal-title":"BMC Health Serv Res"},{"key":"2025112705300699000_10.11.e019634.31","doi-asserted-by":"crossref","DOI":"10.5334\/gh.1186","article-title":"Access to Essential Medicines and Diagnostic Tests for Cardiovascular Diseases in Maputo City, Mozambique","volume":"18","author":"Jessen","year":"2023","journal-title":"Glob Heart"},{"key":"2025112705300699000_10.11.e019634.32","doi-asserted-by":"crossref","first-page":"46958019887572","DOI":"10.1177\/0046958019887572","article-title":"Availability, Price, and Affordability of Essential Medicines to Manage Noncommunicable Diseases: A National Survey From Nepal","volume":"56","author":"Khanal","year":"2019","journal-title":"Inquiry"},{"key":"2025112705300699000_10.11.e019634.33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0255567","article-title":"Evaluation of availability, price, and affordability of cardiovascular, diabetes, and global medicines in Abuja, Nigeria","volume":"16","author":"Osuafor","year":"2021","journal-title":"PLoS ONE"},{"key":"2025112705300699000_10.11.e019634.34","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-017-3980-3","article-title":"Availability of anticancer medicines in public and private sectors, and their affordability by low, middle and high-income class patients in Pakistan","volume":"18","author":"Sarwar","year":"2018","journal-title":"BMC Cancer"},{"key":"2025112705300699000_10.11.e019634.35","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.595008","article-title":"Access to Essential Cardiovascular Medicines in Pakistan: A National Survey on the Availability, Price, and Affordability, Using WHO\/HAI Methodology","volume":"11","author":"Saeed","year":"2020","journal-title":"Front Pharmacol"},{"key":"2025112705300699000_10.11.e019634.36","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-023-09706-y","article-title":"Availability and affordability of anticancer medicines at cancer treating hospitals in Rwanda","volume":"23","author":"Rurangwa","year":"2023","journal-title":"BMC Health Serv Res"},{"key":"2025112705300699000_10.11.e019634.37","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2458-14-817","article-title":"A national survey on availability, price and affordability of selected essential medicines for non communicable diseases in Sri Lanka","volume":"14","author":"Dabare","year":"2014","journal-title":"BMC Public Health"},{"key":"2025112705300699000_10.11.e019634.38","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.4102\/phcfm.v6i1.604","article-title":"Price, availability and affordability of medicines","volume":"6","author":"Mhlanga","year":"2014","journal-title":"Afr J Prim Health Care Fam Med"},{"key":"2025112705300699000_10.11.e019634.39","doi-asserted-by":"crossref","first-page":"850","DOI":"10.26719\/emhj.23.117","article-title":"Prices, availability and affordability of selected essential medicines for chronic diseases in T\u00fcrkiye","volume":"26","author":"\u00d6zler","year":"2023","journal-title":"East Mediterr Health J"},{"key":"2025112705300699000_10.11.e019634.40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0241555","article-title":"Variation in the availability and cost of essential medicines for non-communicable diseases in Uganda: A descriptive time series analysis","volume":"15","author":"Armstrong-Hough","year":"2020","journal-title":"PLoS ONE"},{"key":"2025112705300699000_10.11.e019634.41","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/1415794","article-title":"Health Facilities\u2019 Readiness to Manage Hypertension and Diabetes Cases at Primary Health Facilities in Bidibidi Refugee Settlement, Yumbe District, Uganda","volume":"2021","author":"Isadru","year":"2021","journal-title":"J Trop Med"},{"key":"2025112705300699000_10.11.e019634.42","doi-asserted-by":"crossref","first-page":"140","DOI":"10.55320\/mjz.44.3.279","article-title":"Availability of Essential Antihypertensive and Antidiabetic Medicines in Public Health Facilities in Lusaka District, Zambia","volume":"44","author":"Kalungia","year":"2017","journal-title":"mjz"},{"key":"2025112705300699000_10.11.e019634.43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0226169","article-title":"Availability, prices and affordability of essential medicines for treatment of diabetes and hypertension in private pharmacies in Zambia","volume":"14","author":"Kaiser","year":"2019","journal-title":"PLoS ONE"},{"key":"2025112705300699000_10.11.e019634.44","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-024-11935-8","article-title":"Availability, price, and affordability of diabetes mellitus and thyroid dysfunction medicines in South Wollo zone, Northeast Ethiopia","volume":"24","author":"Mohammed","year":"2024","journal-title":"BMC Health Serv Res"},{"key":"2025112705300699000_10.11.e019634.45","doi-asserted-by":"crossref","DOI":"10.1186\/s41256-024-00352-3","article-title":"Access to essential medicines for diabetes care: availability, price, and affordability in central Ethiopia","volume":"9","author":"Deressa","year":"2024","journal-title":"Glob Health Res Policy"},{"key":"2025112705300699000_10.11.e019634.46","doi-asserted-by":"crossref","DOI":"10.1155\/2024\/6551639","article-title":"Availability and Price Variations of Commonly Used Cardiovascular Medicines at Community and Hospital Pharmacies in Gondar Town, Northwest Ethiopia","volume":"2024","author":"Limenh","year":"2024","journal-title":"Biomed Res Int"},{"key":"2025112705300699000_10.11.e019634.47","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-82919-1","article-title":"Availability, price and affordability of essential medicines for managing cardiovascular disease in Addis Ababa, Ethiopia","volume":"14","author":"Masresha","year":"2024","journal-title":"Sci Rep"},{"key":"2025112705300699000_10.11.e019634.48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0309350","article-title":"Availability, price and affordability of insulin, delivery devices and self-monitoring blood glucose devices in Indonesia","volume":"19","author":"Ramadaniati","year":"2024","journal-title":"PLoS ONE"},{"key":"2025112705300699000_10.11.e019634.49","doi-asserted-by":"crossref","first-page":"e492","DOI":"10.1016\/S2214-109X(18)30563-1","article-title":"Effect of Novartis Access on availability and price of non-communicable disease medicines in Kenya: a cluster-randomised controlled trial","volume":"7","author":"Rockers","year":"2019","journal-title":"Lancet Glob Health"},{"key":"2025112705300699000_10.11.e019634.50","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2020-003116","article-title":"Solving the problem of access to cardiovascular medicines: revolving fund pharmacy models in rural western Kenya","volume":"5","author":"Tran","year":"2020","journal-title":"BMJ Glob Health"},{"key":"2025112705300699000_10.11.e019634.51","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2010.03053.x"},{"key":"2025112705300699000_10.11.e019634.52","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-021-06800-x","article-title":"Improving access to medicines for non-communicable diseases in rural primary care: results from a quasi-randomized cluster trial in a district in South India","volume":"21","author":"Pati","year":"2021","journal-title":"BMC Health Serv Res"},{"key":"2025112705300699000_10.11.e019634.53","doi-asserted-by":"crossref","first-page":"2372033","DOI":"10.1080\/20523211.2024.2372033","article-title":"Access to childhood cancer medicines in South Africa: a health systems analysis of barriers and enablers","volume":"17","author":"Joosse","year":"2024","journal-title":"J Pharm Policy Pract"},{"key":"2025112705300699000_10.11.e019634.54","doi-asserted-by":"crossref","first-page":"e1314","DOI":"10.1016\/S2214-109X(21)00287-4","article-title":"Determinants of access to childhood cancer medicines: a comparative, mixed-methods analysis of four Caribbean countries","volume":"9","author":"Boateng","year":"2021","journal-title":"Lancet Glob Health"},{"key":"2025112705300699000_10.11.e019634.55","doi-asserted-by":"crossref","unstructured":"Shukar S , Yang C , Khan SA , et al . Anti-cancer medicine shortages in an oncology tertiary hospital of Pakistan: A five-year retrospective study. J Oncol Pharm Pract 2022. doi:10.1177\/10781552221114278","DOI":"10.1177\/10781552221114278"},{"key":"2025112705300699000_10.11.e019634.56","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1200\/JGO.19.00300","article-title":"Access to WHO Essential Medicines for Childhood Cancer Care in Trinidad and Tobago: A Health System Analysis of Barriers and Enablers","volume":"6","author":"Tang","year":"2020","journal-title":"JCO Glob Oncol"},{"key":"2025112705300699000_10.11.e019634.57","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2020-002906","article-title":"Health system determinants of access to essential medicines for children with cancer in Ghana","volume":"5","author":"Boateng","year":"2020","journal-title":"BMJ Glob Health"},{"key":"2025112705300699000_10.11.e019634.58","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph192316373","article-title":"Experience of Pharmacists with Anti-Cancer Medicine Shortages in Pakistan: Results of a Qualitative Study","volume":"19","author":"Shukar","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"2025112705300699000_10.11.e019634.59","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-024-11285-5","article-title":"Access to essential and innovative anti-cancer medicines: a longitudinal study in Nanjing, China","volume":"24","author":"Cao","year":"2024","journal-title":"BMC Health Serv Res"},{"key":"2025112705300699000_10.11.e019634.60","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1470-2045(23)00072-4","article-title":"Access to essential cancer medicines for children: a comparative mixed-methods analysis of availability, price, and health-system determinants in east Africa","volume":"24","author":"Petricca","year":"2023","journal-title":"Lancet Oncol"},{"key":"2025112705300699000_10.11.e019634.61","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-022-07738-4","article-title":"The availability of essential medicines for diabetes at health facilities in Bangladesh: evidence from 2014 and 2017 national surveys","volume":"22","author":"Hakim","year":"2022","journal-title":"BMC Health Serv Res"},{"key":"2025112705300699000_10.11.e019634.62","doi-asserted-by":"crossref","first-page":"5","DOI":"10.5588\/pha.20.0033","article-title":"Evaluating the availability of essential drugs for hypertension, diabetes and asthma in rural Rwanda, 2018","volume":"11","author":"Mbonyinshuti","year":"2021","journal-title":"Public Health Action"},{"key":"2025112705300699000_10.11.e019634.63","first-page":"105","article-title":"Enhancing global access to cancer medicines","volume":"70","author":"Cortes","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"2025112705300699000_10.11.e019634.64","doi-asserted-by":"crossref","first-page":"535","DOI":"10.15171\/ijhpm.2016.44","article-title":"Correcting India\u2019s Chronic Shortage of Drug Inspectors to Ensure the Production and Distribution of Safe, High-Quality Medicines","volume":"5","author":"Kadam","year":"2016","journal-title":"Int J Health Policy Manag"},{"key":"2025112705300699000_10.11.e019634.65","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S2213-2600(15)00004-1","article-title":"Burden of asthma and chronic obstructive pulmonary disease and access to essential medicines in low-income and middle-income countries","volume":"3","author":"Beran","year":"2015","journal-title":"Lancet Respir Med"},{"key":"2025112705300699000_10.11.e019634.66","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0001154","article-title":"The availability of essential medicines for cardiovascular diseases at healthcare facilities in low- and middle-income countries: The case of Bangladesh","volume":"2","author":"Hakim","year":"2022","journal-title":"PLOS Glob Public Health"},{"key":"2025112705300699000_10.11.e019634.67","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.sapharm.2019.11.015","article-title":"Access to cancer medication in public hospitals in a middle-income country: The view of stakeholder","volume":"16","author":"Moye-Holz","year":"2020","journal-title":"Res Social Adm Pharm"},{"key":"2025112705300699000_10.11.e019634.68","doi-asserted-by":"publisher","DOI":"10.1200\/JGO.17.00175"},{"key":"2025112705300699000_10.11.e019634.69","doi-asserted-by":"publisher","DOI":"10.1111\/tmi.13497"},{"key":"2025112705300699000_10.11.e019634.70","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s40273-013-0095-9","article-title":"The availability, pricing and affordability of three essential asthma medicines in 52 low- and middle-income countries","volume":"31","author":"Babar","year":"2013","journal-title":"Pharmacoeconomics"},{"key":"2025112705300699000_10.11.e019634.71","doi-asserted-by":"crossref","DOI":"10.3402\/gha.v8.27942","article-title":"The availability of essential medicines for mental healthcare in Sofala, Mozambique","volume":"8","author":"Wagenaar","year":"2015","journal-title":"Glob Health Action"},{"key":"2025112705300699000_10.11.e019634.72","doi-asserted-by":"crossref","DOI":"10.1186\/s12939-017-0651-6","article-title":"Access to medicines and diagnostic tests integral in the management of diabetes mellitus and cardiovascular diseases in Uganda: insights from the ACCODAD study","volume":"16","author":"Kibirige","year":"2017","journal-title":"Int J Equity Health"},{"key":"2025112705300699000_10.11.e019634.73","doi-asserted-by":"crossref","DOI":"10.5334\/aogh.2729","article-title":"Availability, Costs and Stock-Outs of Essential NCD Drugs in Three Rural Rwandan Districts","volume":"86","author":"Mukundiyukuri","year":"2020","journal-title":"Ann Glob Health"},{"key":"2025112705300699000_10.11.e019634.74","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.jval.2017.05.023","article-title":"Effects of Transitioning to Medicare Part D on Access to Drugs for Medical Conditions among Dual Enrollees with Cancer","volume":"20","author":"Adams","year":"2017","journal-title":"Value Health"},{"key":"2025112705300699000_10.11.e019634.75","doi-asserted-by":"crossref","first-page":"100180","DOI":"10.1016\/j.jcpo.2018.12.001","article-title":"Are essential medicines available, reliable and affordable in low-middle income countries?","volume":"19","author":"Eden","year":"2019","journal-title":"J Cancer Policy"},{"key":"2025112705300699000_10.11.e019634.76","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13099"},{"key":"2025112705300699000_10.11.e019634.77","article-title":"Insulin: prices, availability, and affordability in public and private Peruvian pharmacies","volume":"43","author":"Tenorio-Mucha","year":"2019","journal-title":"Rev Panam Salud Publica"},{"key":"2025112705300699000_10.11.e019634.78","doi-asserted-by":"crossref","DOI":"10.1186\/s41256-024-00365-y","article-title":"Strengthening access to cancer medicines for children in East Africa: policy options to enhance medicine procurement, forecasting, and regulations","volume":"9","author":"Petricca","year":"2024","journal-title":"Glob Health Res Policy"},{"key":"2025112705300699000_10.11.e019634.79","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/inthealth\/ihy012","article-title":"Challenges constraining insulin access in Nepal\u2014a country with no local insulin production","volume":"10","author":"Sharma","year":"2018","journal-title":"Int Health"},{"key":"2025112705300699000_10.11.e019634.80","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2023-012309","article-title":"Alignment in the registration, selection, procurement and reimbursement of essential medicines for childhood cancers in South Africa","volume":"8","author":"Joosse","year":"2023","journal-title":"BMJ Glob Health"},{"key":"2025112705300699000_10.11.e019634.81","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.008722"},{"key":"2025112705300699000_10.11.e019634.82","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11892-018-1019-z","article-title":"Availability and Affordability of Essential Medicines: Implications for Global Diabetes Treatment","volume":"18","author":"Beran","year":"2018","journal-title":"Curr Diab Rep"},{"key":"2025112705300699000_10.11.e019634.83","unstructured":"Asare B . Price and Availability of Medicines for Non-Communicable Diseases in Ghana. Accra: Republic of Ghana Ministry of Health, 2024."},{"key":"2025112705300699000_10.11.e019634.84","doi-asserted-by":"publisher","DOI":"10.4103\/jod.jod_106_22"},{"key":"2025112705300699000_10.11.e019634.85","doi-asserted-by":"crossref","DOI":"10.1186\/s40545-022-00481-5","article-title":"Using government data to understand the use and availability of medicines for hypertension and diabetes: lessons from Peru","volume":"15","author":"Tenorio-Mucha","year":"2022","journal-title":"J Pharm Policy Pract"},{"key":"2025112705300699000_10.11.e019634.86","unstructured":"World Health Organization . Strengthening noncommunicable disease integration in all-hazards emergency preparedness and response: policy brief. Geneva, 2025."},{"key":"2025112705300699000_10.11.e019634.87","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2017-000519","article-title":"Preparedness for delivering non-communicable disease services in primary care: access to medicines for diabetes and hypertension in a district in south India","volume":"2","author":"Elias","year":"2017","journal-title":"BMJ Glob Health"},{"key":"2025112705300699000_10.11.e019634.88","doi-asserted-by":"crossref","DOI":"10.1186\/s40545-019-0190-1","article-title":"Challenges constraining availability and affordability of insulin in Bengaluru region (Karnataka, India): evidence from a mixed-methods study","volume":"12","author":"Satheesh","year":"2019","journal-title":"J Pharm Policy Pract"},{"key":"2025112705300699000_10.11.e019634.89","doi-asserted-by":"crossref","DOI":"10.7189\/jogh.12.04063","article-title":"Availability of two essential medicines for mental health in Bangladesh, the Democratic Republic of Congo, Haiti, Nepal, Malawi, Senegal, and Tanzania: Evidence from nationally representative samples of 7958 health facilities","volume":"12","author":"Rahman","year":"2022","journal-title":"J Glob Health"},{"key":"2025112705300699000_10.11.e019634.90","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1017\/S2045796016001165","article-title":"Mapping actions to improve access to medicines for mental disorders in low and middle income countries","volume":"26","author":"Barbui","year":"2017","journal-title":"Epidemiol Psychiatr Sci"},{"key":"2025112705300699000_10.11.e019634.91","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-038842","article-title":"Availability of equipment and medications for non-communicable diseases and injuries at public first-referral level hospitals: a cross-sectional analysis of service provision assessments in eight low-income countries","volume":"10","author":"Gupta","year":"2020","journal-title":"BMJ Open"},{"key":"2025112705300699000_10.11.e019634.92","doi-asserted-by":"crossref","DOI":"10.1080\/20523211.2025.2466215","article-title":"Access to single-inhaler triple medicines for chronic obstructive pulmonary disease in China: a national survey on accessibility and utilisation","volume":"18","author":"Li","year":"2025","journal-title":"J Pharm Policy Pract"},{"key":"2025112705300699000_10.11.e019634.93","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2013-2946"},{"key":"2025112705300699000_10.11.e019634.94","doi-asserted-by":"publisher","DOI":"10.1177\/1010539510373005"},{"key":"2025112705300699000_10.11.e019634.95","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4103\/jod.jod_114_22","article-title":"Accessibility and availability of insulin: A survey by International Diabetes Federation-Middle East and North Africa Region (IDF-MENA) Member Associations","volume":"13","author":"Saad","year":"2022","journal-title":"Journal Of Diabetology"},{"key":"2025112705300699000_10.11.e019634.96","unstructured":"Economist Intelligence Unit . Cancer medicines shortages in europe policy: recommendations to prevent and manage shortages. London The Economist; 2017."},{"key":"2025112705300699000_10.11.e019634.97","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/978-3-319-43896-2_6","article-title":"The Drug Shortage Crisis in the United States: Impact on Cancer Pharmaceutical Safety","volume":"171","author":"Nonzee","year":"2019","journal-title":"Cancer Treat Res"},{"key":"2025112705300699000_10.11.e019634.98","doi-asserted-by":"crossref","first-page":"iii20","DOI":"10.1093\/heapol\/czz057","article-title":"Access to essential cardiovascular medicines for children: a pilot study of availability, price and affordability in Nigeria","volume":"34","author":"Orubu","year":"2019","journal-title":"Health Policy Plan"},{"key":"2025112705300699000_10.11.e019634.99","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2261-10-25","article-title":"Availability, price and affordability of cardiovascular medicines: a comparison across 36 countries using WHO\/HAI data","volume":"10","author":"van Mourik","year":"2010","journal-title":"BMC Cardiovasc Disord"},{"key":"2025112705300699000_10.11.e019634.100","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1002\/cncr.33568","article-title":"Forecasting essential childhood cancer drug need: An innovative model-based approach","volume":"127","author":"Hughes","year":"2021","journal-title":"Cancer"},{"key":"2025112705300699000_10.11.e019634.101","doi-asserted-by":"publisher","DOI":"10.1200\/JGO.17.00175"},{"key":"2025112705300699000_10.11.e019634.102","doi-asserted-by":"publisher","DOI":"10.1111\/tmi.13593"},{"key":"2025112705300699000_10.11.e019634.103","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1080\/23288604.2019.1596050","article-title":"Improving Supply Chain for Essential Drugs in Low-Income Countries: Results from a Large Scale Randomized Experiment in Zambia","volume":"5","author":"Vledder","year":"2019","journal-title":"Health Syst Reform"},{"key":"2025112705300699000_10.11.e019634.104","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/cpt.1680","article-title":"The World Health Organization Prequalification Program and Clinical Pharmacology in 2030","volume":"107","author":"Blaschke","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"2025112705300699000_10.11.e019634.105","doi-asserted-by":"crossref","first-page":"102996","DOI":"10.1016\/j.jhealeco.2025.102996","article-title":"Procurement institutions and essential drug supply in low and middle-income countries","volume":"101","author":"Wang","year":"2025","journal-title":"J Health Econ"},{"key":"2025112705300699000_10.11.e019634.106","unstructured":"World Health Organization Regional Office for Europe . Challenges and opportunities in improving access to medicines through efficient public procurement in the who european region. Copenhagen, 2016."},{"key":"2025112705300699000_10.11.e019634.107","doi-asserted-by":"crossref","first-page":"142","DOI":"10.4161\/23288604.2014.968005","article-title":"Health Product Supply Chains in Developing Countries: Diagnosis of the Root Causes of Underperformance and an Agenda for Reform","volume":"1","author":"Yadav","year":"2015","journal-title":"Health Syst Reform"},{"key":"2025112705300699000_10.11.e019634.108","unstructured":"Chapman S , Szklanowska A , Lopert R . Exploring the Feasibility of Monitoring Access to Novel Medicines: A Pilot Study in EU Member States. Paris: OECD Publishing, 2023."}],"container-title":["BMJ Global Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgh-2025-019634","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T13:30:37Z","timestamp":1764250237000},"score":1,"resource":{"primary":{"URL":"https:\/\/gh.bmj.com\/lookup\/doi\/10.1136\/bmjgh-2025-019634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":108,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,27]]},"published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1136\/bmjgh-2025-019634"],"URL":"https:\/\/doi.org\/10.1136\/bmjgh-2025-019634","relation":{},"ISSN":["2059-7908"],"issn-type":[{"value":"2059-7908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]}}}